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Abstract
We report the development and optimization of reagents for in-solution, hybridization-based capture of the mouse
exome. By validating this approach in a multiple inbred strains and in novel mutant strains, we show that whole
exome sequencing is a robust approach for discovery of putative mutations, irrespective of strain background. We
found strong candidate mutations for the majority of mutant exomes sequenced, including new models of
orofacial clefting, urogenital dysmorphology, kyphosis and autoimmune hepatitis.
Background
Phenotype-driven approaches in model organisms, includ-
ing spontaneous mutation discovery, standard N-ethyl-N-
nitrosourea (ENU) mutagenesis screens, sensitized screens
and modifier screens, are established approaches in func-
tional genomics for the discovery of novel genes and/or
novel gene functions. As over 90% of mouse genes have an
ortholog in the human genome [1], the identification of
causative mutations in mice with clinical phenotypes can
directly lead to the discovery of human disease genes.
However, mouse mutants with clinically relevant pheno-
types are not maximally useful as disease models until the
underlying causative mutation is identified. Until recently,
the gene discovery process in mice has been straightfor-
ward, but greatly hindered by the time and expense
incurred by high-resolution recombination mapping. Now,
the widespread availability of massively parallel sequencing
[2] has brought about a paradigm shift in forward genetics
by closing the gap between phenotype and genotype.
Both selective sequencing and whole genome sequencing
are robust methods for mutation discovery in the mouse
genome [3-5]. Nonetheless, the sequencing and analysis of
whole mammalian genomes remains computationally
burdensome and expensive for many laboratories. Targeted
sequencing approaches are less expensive and the data are
accordingly more manageable, but this technique requires
substantial genetic mapping and the design and purchase
of custom capture tools (that is, arrays or probe pools) [4].
Targeted sequencing of the coding portion of the genome,
the ‘exome’, provides an opportunity to sequence mouse
mutants with minimal mapping data and alleviates the
need for a custom array/probe pool for each mutant. This
approach, proven to be highly effective for the discovery of
coding mutations underlying single gene disorders in
humans [6-12], is particularly relevant to large mutant col-
lections, where high-throughput gene discovery methods
are desirable.
Currently, there are nearly 5,000 spontaneous and
induced mouse mutant alleles with clinically relevant phe-
notypes catalogued in the Mouse Genome Informatics
database [13]. The molecular basis of the lesions underly-
ing two-thirds of these phenotypes is currently unknown.
For the remaining one-third that have been characterized,
the Mouse Genome Informatics database indicates that
92% occur in coding sequence or are within 20 bp of
intron/exon boundaries, regions that are purposefully cov-
ered by exome targeted re-sequencing. While this estimate
is impacted by an unknown degree of ascertainment bias
(since coding or splice site mutations are easier to find
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mutations remain so because they are understudied), we
anticipated that exome sequencing would still be likely to
c a p t u r eac o n s i d e r a b l ep e r c e n t a g eo fs p o n t a n e o u sa n d
induced mouse mutations. Therefore, to significantly
reduce the time, effort, and cost of forward genetic
screens, we developed a sequence capture probe pool
representing the mouse exome. Here, we describe the uti-
lity of this tool for exome sequencing in both wild-type
inbred and mutant strain backgrounds, and demonstrate
success in discovering both spontaneous and induced
mutations.
Results and discussion
Mouse exome content and capture probe design
The coding sequence selected for the mouse exome
probe pool design includes 203,225 exonic regions,
including microRNAs, and collectively comprises over
54.3 Mb of target sequence (C57BL/6J, NCBI37/mm9).
The design was based on a unified, Mouse Genome Data-
base-curated gene set, consisting of non-redundant gene
predictions from the National Center for Biotechnology
Information (NCBI), Ensembl and The Vertebrate
Genome Annotation (VEGA) database [13]. The gene list
is available at [14]. To manage the size of the probe pool
and to avoid non-uniquely mappable regions, we
excluded olfactory receptors and pseudogenes from the
target sequence. In cases where an exon contained both
UTR and coding sequence, the UTR sequence was
included in the design. Two DNA probe pools, alpha and
beta prototypes, were ultimately designed and tested. To
maximize the uniformity of the sequencing libraries after
capture, re-sequencing data from the alpha prototype
design were empirically studied and used to inform a
coverage re-balancing algorithm. That algorithm altered
the probe coverage target ratio of a second design (beta
prototype) in an attempt to decrease over-represented
sequence coverage, and increase under-represented
sequence coverage. The target (primary design) coordi-
nates and the coordinates of the capture probes in the
beta design are available at [15]. The summary statistics
for each probe pool are shown in Additional file 1.
Exome capture performance and optimization
T ot e s tt h ea l p h aa n db e t ae x o m ep r o b ep o o l sa n dt o
determine whether strain background adversely influ-
enced performance, exomes from four commonly used
inbred strains (C57BL/6J, 129S1/SvImJ, BALB/cJ and
C3H/HeJ) were captured and re-sequenced (Table 1).
Overall, capture sensitivity was high, with just one lane of
2 × 40-bp paired-end sequencing (2 × 40 bp PE) resulting
in > 96% of the targeted bases covered. The capture spe-
cificity was also high with > 75% reads mapping to tar-
geted bases. Importantly, the sequencing data were
significantly enriched, not only for coding sequence but
also for flanking splice acceptor and donor sites, where
deleterious mutations are frequently found (Figure 1).
Genetic background only modestly impacted the sensitiv-
ity and specificity of the capture probe pools. The varia-
tion between strains was greater than within a strain
(Table 1); however, the scale of the inter-strain differ-
ences observed suggests that a pool based upon exclu-
sively the mm9 reference would be functional with any
Mus musculus background.
The beta design was made using a proprietary reba-
lancing algorithm from Roche NimbleGen (Madison,
WI, USA) that removes probes from targets with high
coverage and adds probes to low coverage targets in
order to maximize coverage across targets. In addition
to testing the beta design by exome capture and 2 × 40
bp PE Illumina sequencing of four different inbred
strains, the beta design was also tested with four inde-
pendent captures of C57BL/6J female DNA and
sequenced on the Illumina GAII platform, 2 × 76 bp PE.
The most dramatic improvement was observed in the
fraction of targeted bases covered at 20× or more where
the increase in uniformity resulted in 12% improvement
(Additional file 2).
Sequencing of mutant exomes
To determine the efficacy of the probe pools for mutant
exome re-sequencing and mutation discovery, 15 novel
mouse mutant exomes and 3 controls were captured and
sequenced at multiple sites using different Illumina plat-
forms (Illumina GAIIx, Illumina HiSeq, and both 2 × 76-
bp and 2 × 100-bp PE libraries). The mutants were
selected based on several parameters, including research
area, mode of inheritance (dominant and recessive), strain
background, and mutation type (induced and sponta-
neous). Where appropriate, homozygous samples were
captured and sequenced (Additional file 3). In all cases,
the beta exome pools provided improved capture unifor-
mity. In the majority of cases, > 97% of targeted bases
were covered by at least one read (1×). Approximately 45
million 100-bp PE reads were sufficient, on average, to
provide at least 5 reads coverage of 95% of target bases
(Table 2; Additional file 4), which is sufficient for detection
of recessive mutations in homozygous samples. To confi-
dently call heterozygous alleles, at least 15× coverage is
preferable [4], and these data show that more than 58 mil-
lion, 100-bp PE reads are likely required to obtain a mini-
mum of 15 reads across 95% of target bases. Therefore, we
anticipate that sample indexing schemes may soon enable
as many as four exomes to be multiplexed per lane of an
Illumina HiSeq run using the most current reagents. The
raw sequencing data for mutant and inbred strains are
available from the NCBI Sequence Read Archive (acces-
sion number [SRP007328]).
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Mapping to the mouse reference sequence (C57BL/6J,
NCBI37/mm9) and subsequent variant calling resulted in
a number of single nucleotide variants (SNVs) and inser-
tions/deletions (INDELs) ranging from approximately
8,000 (C57BL/6J background) to over 200,000 (for more
divergent strain backgrounds) variant calls per mutant
exome, depending on strain background and depth of
coverage. Generally, approximately two-thirds of the var-
iants called were SNVs, rather than INDELS. However, in
mutants on the C57BL/6J background, this ratio was clo-
ser to approximately one-half (Additional file 3). This is
not surprising given that a large proportion of false posi-
tive calls from reference guided assembly are INDELs
and the number of true variants in any C57BL/6J exome
is expected to be low because the mouse reference strain
is, primarily, C57BL/6J. The one exception was mutant
12860 (nert), which was reported to be on a C57BL/6J
background; however, the relatively large number of var-
iants detected in this mutant exome could indicate that
the reported strain background is likely incorrect.
Variant annotation and nomination of candidate
mutations
The variant data were fully annotated according to
genomic position, SNV quality, allele ratio (number of
reads containing variant allele/number of reads contain-
ing reference allele), and overlap with current genome
Table 1 Direct comparison of coverage statistics from exome re-sequencing (2 × 40 bp, Illumina) of four inbred strains
with two exome probe pool designs, alpha and beta
Sample
C57BL/6J C57BL/6J 129S1/SvImJ 129S1/SvImJ BALB/cJ BALB/cJ C3H/HeJ C3H/HeJ
Exome version Alpha Beta Alpha Beta Alpha Beta Alpha Beta
Quantitative PCR 161.81 168.53 129.43 95.75 168.92 165.08 168.38 92.00
Target exons 203,225 203,224 203,225 203,224 203,225 203,224 203,225 203,224
Target bases 54,367,346 54,367,244 54,367,346 54,367,244 54,367,346 54,367,244 54,367,346 54,367,244
Target bases covered 52,266,238 53,273,874 51,746,839 52,508,881 51,828,334 52,862,662 52,136,965 51,460,949
Percentage target bases covered 96.14 97.99 95.18 96.58 95.33 97.23 95.90 94.65
Target bases not covered 2,101,108 1,093,370 2,620,507 1,858,363 2,539,012 1,504,582 2,230,381 2,906,295
Percentage target bases not covered 3.86 2.01 4.82 3.42 4.67 2.77 4.10 5.35
Median coverage 18.45 20.74 17.93 16.37 18.05 20.75 18.76 7.86
Total reads 60,582,097 60,207,746 64,258,556 44,434,168 64,495,816 63,740,186 64,959,026 25,760,946
NC80 0.28 0.37 0.25 0.33 0.25 0.31 0.29 0.32
1/NC80 3.53 2.71 4.03 3.02 3.96 3.27 3.50 3.13
1/NC80 is the fold 80 penalty, which represents the fold of over-sequencing necessary to move 80% of the below median bases to median.
(a) (b)
Figure 1 Graphical view (Integrated Genomics Viewer) of read distribution across a gene and an exon . (a,b) Gene (a) and exon (b)
annotations shown are from the primary representative RefSeq annotations. The exome design encompasses a unified set of exon annotations
from NCBI, Ensembl and VEGA; therefore, there are regions with high coverage, representing exons that are not shown in the primary RefSeq
annotation (red arrow) but are represented in Ensembl and/or VEGA. Typical coverage across exons includes sufficient read depth to call single
nucleotide variants in coding sequence and in neighboring splice acceptor and donor sites, as well as 20 to 50 bases of additional flanking
intron sequence (b).
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(RefSeq)/Ensembl genes, exons, introns, splice sites, and
known SNVs, INDELs (the Single Nucleotide Poly-
morphism database, dbSNP). In each case, existing link-
age data were used to determine map positions and the
analysis was then limited to those regions. The existing
l i n k a g ed a t ar a n g e df r o mc o a r s e( c h r o m o s o m a ll i n k a g e )
to fine (regions of < 10 to 20 Mb) (Additional file 3).
The most likely causative mutations for each mutant
sample and for a control C57BL/6J exome were nomi-
nated using the annotations as shown in Table 3. Speci-
fically, novel (when compared to dbSNP) protein coding
or splice site variants falling within mapped regions,
with expected allele ratios (> 0.95 for homozygous var-
iants and > 0.2 for heterozygous variants) were given
priority for validation by re-sequencing of additional
mutant and unaffected samples. To further reduce the
validation burden, we found that comparison of unre-
lated exome sequencing data sets and comparison to the
Sanger Institute Mouse Genomes data [16] allowed for
significant reduction in validation burden, as any var-
iants common between these data sets represent com-
mon variants that are shared between related strains or
systematic false positives arising from mapping the data
back to the reference sequence. Similar to what has
been observed in human exome sequencing, the latter
can be caused by repetitive or closely related sequences
(paralogs) or underlying deficiencies in the reference
sequence. For comparison, the alignment data from the
C57BL/6J beta exome shown in Table 1 were subjected
to variant calling and annotation. Interestingly, 17 var-
iants passed filters in a C57BL/6J exome (Table 3),
expected to be most similar to the reference genome,
which is also primarily C57BL/6J. Comparison of these
variants with the high throughput sequencing data for
17 inbred strains available from Sanger Mouse Genomes
Project revealed three exonic SNVs unique to the
C57BL/6J exome. We predict that the remaining 14 var-
iants calls are false positive calls due to mapping errors,
which can arise in regions where there is underlying
deficiency in the reference sequence or in regions that
share sequence similarity (that is, paralogs). These
regions are apparent when viewing alignments as
regions that contain a preponderance of non-uniquely
mapped reads, gaps, or regions that contain apparent
heterozygosity in samples that are known to be homozy-
gous (as is the case with the inbred strain data from the
Sanger Mouse Genomes project, where each strain was
subjected to at least 200 generations of brother × sister
intercrossing prior to sequencing; Additional file 5).
Validation of putative causative mutations
Using this approach, only one or two variants were nomi-
nated for validation in each of nine mutant exomes. Four
of these mutants represented ENU-generated lines, while
five were spontaneous mutants. In a few cases, the single
variant nominated for validation proved to be the likely
causative mutation. For example, the single SNV nomi-
nated for validation in the bloodline mutant correlated
with the phenotype when additional affected and
Table 2 Representative coverage statistics from exome re-sequencing (2 × 100 bp) of six mutant strains
Sample
5330 (hbck) 6246 (sunk) 8568 (lear) 12856 (shep) 13782 (aphl) 13716 (vgim)
Targeted exons 203,224 203,224 203,224 203,224 203,224 203,224
Final target bases 54,367,244 54,367,244 54,367,244 54,367,244 54,367,244 54,367,244
Target bases covered 52,934,978 52,493,811 52,832,014 52,647,881 52,664,921 53,004,900
Percentage target bases covered 97.37 96.55 97.18 96.84 96.87 97.49
Target bases not covered 1,432,266 1,873,433 1,535,230 1,719,363 1,702,323 1,362,344
Percentage target bases not covered 2.63 3.45 2.82 3.16 3.13 2.51
Total reads
a 39,675,108 39,641,830 31,817,686 42,405,386 59,956,764 67,359,382
Number of reads in target regions 23,319,015 23,335,916 19,211,748 25,227,205 36,227,876 39,948,582
Percentage reads in target regions 58.77 58.87 60.38 59.49 60.42 59.31
Average coverage 32.72 32.59 26.75 35.32 50.78 56.31
Median coverage 30.33 30.02 23.23 33.02 46.61 50.02
Coverage at 20× 76.4 73.6 61.9 77.5 85.8 88
Coverage at 10× 92.1 89.3 87.1 90.7 92.9 94.5
Coverage at 5× 95.7 93.8 94.3 94.4 95.1 96.2
Coverage at 1× 97.4 96.6 97.2 96.8 96.9 97.5
NC80 0.51 0.47 0.46 0.49 0.47 0.46
1/NC80 1.94 2.13 2.18 2.06 2.13 2.17
1/NC80 is the fold 80 penalty, which represents the fold of over sequencing necessary to move 80% of the below median bases to median. Coverage statistics
for all samples sequenced can be found in Additional file 3.
a2 × 100 bp, Illumina HiSeq.
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missense mutation causing an amino acid change (E293K)
in Map3K11, a gene that encodes a mitogen-activated pro-
tein kinase kinase kinase that is involved in a variety of cel-
lular signaling cascades. Importantly, mice homozygous
for a targeted null mutation in Map3k11 have the charac-
teristic epidermal midline defect that is also observed in
bloodline homozygotes [17], further implicating the mis-
sense mutation found as the causative mutation. Unlike
bloodline homozygotes, Map3K11-/- mice are viable and
tooth pulp necrosis has not been reported [17], indicating
that the spontaneous mutation may be sensitive to strain
background effects. However, further work is needed to
establish the underlying mechanisms influencing these
phenotypic differences.
In some cases, more than one potentially damaging
variant was found to correlate with the phenotype when
additional affected and unaffected animals from the pedi-
gree were genotyped (Table 3). In two cases, hpbk and
vgim, where more than one variant was found, only one
variant could be validated while the other variants were
false positives. In two cases where more than one poten-
tially damaging variant was found, both were validated.
Not surprisingly, these cases were ENU-induced mutant
exomes (Cleft and l11Jus74) and ENU is known to cause
mutations at a rate of greater than 1 in 750 per locus per
gamete [18] at doses of 85 mg/kg. Cleft is a dominant
craniofacial ENU mutation that causes cleft palate. Of
the two variants that were nominated for validation, both
were SNVs residing in Col2a1,ag e n ec o d i n gf o rt y p eI I
procollagen. Both SNVs reside within 10 kb of each other
(Chr15:97815207 and Chr15:97825743) in Col2a1, a gene
coding for type II procollagen, and not surprisingly were
found to be concordant with the phenotype when multi-
ple animals from the pedigree were genotyped. The most
likely causative lesion (G to A at Chr15:97815207) is a
nonsense mutation that introduces a premature stop
codon at amino acid 645. The second closely linked var-
iant is an A to T transversion in intron 12 that could
potentially act as a cryptic splice site. However, since RT-
PCR did not reveal splicing abnormalities, it is more
likely that the nonsense mutation is the causative lesion
(Figure 2b). Mice homozygous for targeted deletions in
Col2a1 and mice homozygous for a previously character-
ized, spontaneous mis-sense mutation, Col2a1
sedc,s h a r e
similar defects in cartilage development to Cleft mutants,
including recessive peri-natal lethality and orofacial cleft-
ing [19,20], providing further support that the Cleft phe-
notype is the result of a mutation in Col2a1.
The l11Jus74 mutation was isolated in a screen for
recessive lethal alleles on mouse chromosome 11 using a
129.Inv(11)8Brd
Trp53-Wnt3 balancer chromosome [21,22].
Table 3 Analysis of annotated variant data from mutant exome sequencing
Mutant
number
(allele)
Inheritance/
phenotype
Mutation
type: strain
background
Variants
called
In gene
(introns,
exons)
Novel
SNVs
a
Overlap
with map
position
Allele
ratio
b
Non-synonymous
coding variants,
splice sites
Unique
c Putative
mutation
12874
(bloodline)
Recessive/
metabolic
Spontaneous:
stock (mixed
B6)
134,205 116,120 35,469 350 155 29 1 Map3k11, E293K
12724
(Cleft)
Dominant/
craniofacial
ENU: C57BL/6J,
C3HeB/FeJ
49,367 36,037 10,873 83 53 19 2 Col2a1, Q713Stop
repro7 Recessive/
reproductive
ENU: C57BL/6J,
C3H/HeJ, Cast/
EiJ
410,333 185,999 87,568 799 47 7 1 Prdm9, Q478Stop
5330
(hpbk)
Recessive/
skeletal
ENU: C57BL/6J 8,516 6,167 4,589 35 3 2 2 Notch3, splice
donor site (G to
A), intron 31
13716
(vgim)
Recessive/
reproductive
Spontaneous:
C57BL/6J
10,134 7,346 5,533 117 6 3 2 Lhfpl2, G102E
8568 (lear) Recessive/
small ears
Spontaneous:
C57BL/6J
8,219 5,715 1,889 12 1 1 1 Prkra, intron 5,
splice donor
12856
(shep)
Recessive/
metabolic
Spontaneous:
A/J
164,116 59,067 16,930 454 177 83 1 Relb, Q334K
l11Jus74 Recessive ENU: B6, 129 230,896 52,628 14,448 344 37 4 2 Rundc3a, Y46F;
Nek8, V343E
4235
(Sofa)
Dominant,
craniofacial
Spontaneous:
C57BL/6J, AKR/
J
134,207 116,122 35,471 346 310 121 1 Pfas,
H1194_G1198del
C57BL/6J NA None 5,980 3,953 3,132 NA 538 17 3 NA
13716
(vgim)
Recessive/
reproductive
Spontaneous:
C57BL/6J
10,134 7,346 5,533 NA 940 97 38 NA
aCompared to dbSNP.
b> 0.95 for homozygous samples, > 0.2 for heterozygous samples.
c compared to unrelated exome data sets. NA, not available.
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(d)
(e)
Figure 2 Examples of validated mutations discovered in mutant exome data . The bloodline mutation is a recessive mutation that causes a
distinctive dorsal epidermal defect and tooth pulp necrosis. Exome sequencing revealed a G to A mutation in Map3K11 (mitogen-activated
protein kinase kinase kinase 11). (a) PCR and sequencing of additional mutant (bloodline/bloodline) and unaffected (+/+ or +/-) animals provided
additional support for this putative mutation. The ‘Cleft’ mutation is an ENU mutation that arose on C57BL/6J. The mutation causes a dominant
craniofacial phenotype and recessive perinatal lethality with characteristic cleft palate. (b) Sanger sequencing confirmed the presence of two
closely linked mutations in multiple cleft/+ and cleft/cleft samples and the absence of these mutations in +/+ littermate samples. (c) Of the two
mutations found, the intron mutation has the potential to cause splicing defects, although it is less likely to contribute to the phenotype since
RT-PCR shows no indication of defective splicing mutant samples. The ‘Sofa’ mutation is a spontaneous mutation that arose on C57BL/6J,
causing a dominant craniofacial phenotype and recessive perinatal lethality. (d) Sanger sequencing of heterozygous and control samples
confirmed the presence of a 15-bp deletion in Pfas, FGAR amidotransferase. (e) Reads from the mutant, deletion-bearing allele successfully
mapped to Pfas using BWA (Burrows-Wheeler aligment tool) and the deletion was called using SAMtools [25] with an allele ratio of 0.2.
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C57BL/6J ENU-treated males, mated to the balancer,
which was generated in 129S5SvEv embryonic stem cells.
Embryos from the l11Jus74 l i n ew e r ea n a l y z e df r o m
timed matings, as previously described [23], to determine
that homozygotes die perinatally. Two potentially causa-
tive missense mutations were found in Nek8 (NIMA
(never in mitosis gene a)-related expressed kinase 8;
V343E) and Rundc3a (Run domain containing 3a; Y46F).
Mutations in Nek8 cause polycystic kidney disease, but
no phenotypes have been ascribed to mutations in
Rundc3a. Although the cause of death of l11Jus74 homo-
zygotes has not been determined, polycystic kidneys have
not been observed, making the most likely lesion to result
in perinatal death Rundc3a, although the Nek8 mutation
may cause a delayed onset phenotype.
For all four of the ENU-induced mutant exomes
sequenced, putative causative mutations were nominated
and validated. Mutations induced by ENU are usually sin-
gle nucleotide substitutions. The high sensitivity of cur-
rent analytical pipelines for detecting single nucleotide
substitutions (and particularly homozygous substitu-
tions), combined with the propensity of damaging single
nucleotide substitutions to occur in coding sequences,
likely explains the high success rate of exome sequencing
for detecting induced lesions. Similarly, Boles et al.[ 2 4 ]
showed that targeted sequencing of exons and highly
conserved sequences from ENU mutants mapping to
chromosome 11 yielded a high success rate, with candi-
date mutations nominated in nearly 75% of mutants.
While mutations induced by mutagens like ENU are
known to cause single nucleotide substitutions, sponta-
neous mutations are the result of a variety of lesions,
including single nucleotide substitutions, small INDELS
and larger deletions or insertions of mobile DNA ele-
ments. Of the nine potentially damaging coding or splicing
mutations discovered in this set of mutant exomes, the
spontaneous Sofa mutant was the only one for which a
single nucleotide substitution was not discovered. Instead,
a 15-bp deletion in Pfas (Table 3; Figure 2d,e) was found,
demonstrating that small deletions in coding sequence can
be discovered using this approach.
Interestingly, the allele ratio for the Sofa deletion was
0.2, which is lower than expected for a heterozygote;
therefore, a stringent cutoff of 0.5 or even 0.35, which we
previously found was sufficient for calling heterozygous
variants at approximately 80% confidence [4], would have
eliminated this variant from consideration. The lower
allele ratio is likely the result of bias in either the capture
of the INDEL-containing fragments, and/or the ability to
appropriately map some of the INDEL-bearing reads.
Since the library fragments are larger than both the
probes and the exons they target and because each target
is tiled with multiple probes, there are expected to be
perfect match probes somewhere within an exon for
nearly every allele despite the presence of an INDEL.
Consequently, we favor a mapping problem as the major
driver for the lower than expected allele ratio observed
(Figure 2e). Longer reads may alleviate some systematic
issues associated with discovering relevant deletions or
insertions. A 15-bp deletion would maximally comprise a
mismatch of nearly 38% along a 40-bp read, but only 20%
within a 76-bp read. Large gaps (20% or more of the
read) would impose a stiff mapping penalty on that end
of read pairs. Presumably, longer reads (100 bp or longer)
would incur lower penalties, thereby moderating adverse
mapping effects.
Approximately 10% of known deleterious mutations in
the mouse genome affect the conserved splice acceptor
or donor sites (Table 4), which include the two intronic
nucleotides immediately flanking each exon. Of the puta-
tive mutations discovered in this set of 15 mutant
exomes, three candidates were found in or immediately
adjacent to the conserved splice acceptor or donor sites
(Cleft, lear,a n dhpbk), demonstrating that exome
sequencing provides sufficient coverage of flanking intron
sequence to positively identify potentially damaging, non-
coding mutations in the intron sequences immediately
flanking target exons.
Traditional genetic mapping and exome sequencing
In all cases, either coarse mapping data (chromosomal
linkage) or a fine map position (< 20 Mb) was available to
guide analysis and ease validation burden (Additional file
3). For example, the shep mutation was previously linked
to chromosome 7 (approximately 152 Mb), while repro7
was fine mapped to a 4.5 Mb region on chromosome 17.
The mapping of shep to chromosome 7 was accomplished
using a group of 20 affected animals, while the fine map-
ping of repro7 to a 4.5 Mb region on chromosome 17
required the generation of 524 F2 animals, requiring over
a year of breeding in limited vivarium space. In both cases,
the mapping data coupled with the additional filtering of
annotated data, as shown in Table 3, significantly reduced
the validation burden to a single variant. Therefore, high-
throughput sequencing (exome or whole genome) repre-
sents a cost efficient alternative to fine mapping by recom-
bination, especially in cases where vivarium space and
time are limited resources.
In the absence of chromosomal linkage, the validation
burden is significantly larger. For example, the vgim
mutant exome was reanalyzed without utilizing mapping
information (Table 3, last row) and 38 variants were
nominated for validation. Addition of just the chromoso-
mal linkage data for vgim (chromosome 13), but not the
fine mapping data (chr13:85473357-96594659) reduces
the validation burden to two candidates. Therefore,
coarse mapping to establish chromosomal linkage
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minimal additional animal husbandry cost and time. In
the absence of mapping data and/or when mutations
arise on unusual genetic backgrounds, exome sequencing
of additional samples (affected animal and parents)
would similarly reduce the validation burden to just one
or a few variants.
Limitations of exome sequencing for mutation discovery
Using this technology, we validated putative causative
coding mutations in 9 of the 15 mutant exomes exam-
ined. For the remaining six mutants, candidate mutations
were found in UTRs or were not found at all (Table 5).
For Alf, nert and aphl, candidate mutations were found
in UTRs, and interestingly, in nearly every case, these
candidate mutations are in genes not currently associated
with any mouse phenotype. For the other three mutants,
frg, stn and sunk, no candidate mutations were found in
protein coding sequence, splice sites or in UTRs. Failure
to identify the candidate causative mutations most likely
indicates that these mutations reside in non-coding, reg-
ulatory regions or unannotated coding sequence that is
n o ti n c l u d e di nt h ec u r r e n te x o m ec a p t u r ed e s i g n .A n
additional possibility is that the underlying mutations do
reside in the targeted regions, but are simply not revealed
using standard mapping and SNP calling, which is clearly
biased towards the discovery of single nucleotide substi-
tutions and small INDELs. Robust computational meth-
ods for finding larger insertions and deletions and/or
translocations via high-throughput sequencing data are
not widely available and the absence of these tools limits
spontaneous mutation discovery by any means, whether
exome or whole genome sequencing.
In a parallel effort, we used targeted sequencing of con-
tiguous regions to discover spontaneous mutations that
have been mapped to regions of 10 Mb or less. Interest-
ingly, the success rate for nominating putative mutations
via targeted sequencing of contiguous regions was com-
parable to that of exome sequencing (at approximately
60%), demonstrating that despite the availability of
Table 4 In silico analysis of all induced or spontaneous alleles (4,984) with phenotypes reported in the Mouse
Genomes Database [1]
Mutation Number of
alleles
Unknown or uncharacterized 3,105
Introns, UTRs, regulatory regions (including instances where the lesion is not known but coding sequence has been sequenced),
cryptic splice sites, inversions
150
Exons (single nucleotide substitutions, deletions, insertions) 1,581
Conserved splice acceptor or donor 148
This analysis shows that the vast majority of induced or spontaneous alleles that have been characterized at the molecular level (1,879) are mutations in coding
sequence or conserved splice acceptor/splice donor sites.
Table 5 Validation of putative causative coding mutations in 15 mutant exomes
Mutant
number
(allele)
Inheritance/
phenotype
Strain
background
Variants
called
In gene
(introns,
exons)
Novel
SNVs
a
Overlap
with
map
position
Allele
ratio
b
Non-
synonymous
coding
variants,
splice sites
Unique
c Validation
of coding/
splice
variants
Variants in
UTRs
5413
(Plps)
Dominant/
craniofacial
Spontaneous:
C57BL/6J,
129S1/SvImJ
13,453 3,271 1,821 200 129 55 3 None 3: Kcnab3, Pigs,
Accn1
12860
(nert)
Recessive/
craniofacial
Spontaneous:
C57BL/6J
121,109 105,964 30,275 1,441 639 94 3 None 4:
4931406P16Rik,
Shisa7, Nipa1,
Alpk3
13782
(aphl)
Recessive/
skin, hair
Spontaneous:
MRL/MpJ
182,564 156,802 57,317 554 366 33 1 None 4: Eif2ak3,
Mrpl35, Usp39
(2)
6246
(sunk)
Recessive/
size
Spontaneous:
A/J
164,053 60,051 16,508 693 303 25 0 None None
3485 (frg) Recessive/
craniofacial
Spontaneous:
C57BL/6J, A/J
124,054 105,326 20,073 36 22 0 0 None None
4507
(stn)
Recessive/
craniofacial
Spontaneous:
C57BL/6J
7,523 3,079 2,338 13 7 0 0 None None
In 6 of the 15 mutant exomes sequenced, candidate mutations in protein coding sequence or splice sites were either not found or could not be validated in
additional samples; for three of these, however, candidate mutations in regions annotated at UTRs were identified.
aCompared to dbSNP.
b> 0.95 for
homozygous samples, > 0.2 for heterozygous samples.
ccompared to unrelated exome data sets.
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existing analysis pipelines are not sufficient for discovery
of all disease-causative genetic lesions. Moreover, sys-
tematic errors in the mm9 reference sequence or insuffi-
cient gene annotation [24] are also likely to contribute to
failed mutation discovery, since current analytical
approaches rely upon reference and contemporary gene
annotation as assumed underlying truth.
In this context, it is notable that the exome-based analy-
sis of human phenotypes that are presumed to be mono-
genic is also frequently unsuccessful, although such
negative results are generally not reported in the literature.
Consequently, we anticipate that deeper analysis of the
mouse mutants that fail discovery by exome sequencing
may also shed light on the nature of both non-coding and
cryptic coding mutations that contribute to Mendelian
phenotypes in humans.
Conclusions
Whole exome sequencing is a robust method for muta-
tion discovery in the mouse genome and will be particu-
larly useful for high-throughput genetic analyses of large
mutant collections. Due to the nature of the underlying
mutations and the current methods available for mas-
sively parallel sequence data analysis, ENU mutation dis-
covery via exome sequencing is more successful than
spontaneous mutation discovery. In all cases, coarse
mapping data (chromosomal linkage) significantly eased
validation burden (Table 3); however, fine mapping to
chromosomal regions < 10 to 20 Mb, while useful, did
not provide significant added value (Table 3; Additional
file 3). A similar conclusion was drawn by Arnold et al.
[5] for mutation discovery via whole genome sequencing.
In addition, since the data shown here include mutations
on a variety of strain backgrounds, comparison across
unrelated exome data sets and to whole genome sequen-
cing data from the Mouse Genomes Project [16] proved
critical in reducing the validation burden, especially
where mapping data were not available to guide analysis.
Although we are 10 years past the assembly of both
the human and mouse genomes, the biological function
of the vast majority of mammalian genes remains
unknown. We anticipate that the application of exome
sequencing to the thousands of immediately available
mutant mouse lines exhibiting clinically relevant pheno-
types will make a large and highly valuable contribution
to filling this knowledge gap.
Materials and Methods
Exome capture and sequencing
The following protocol for exome capture and sequen-
cing is the standard protocol generally followed by all
sites providing data for proof-of-concept experiments.
Site-specific deviations in the standard protocol can be
provided upon request. The mouse exome probe pools
developed in this study, SeqCap EZ Mouse Exome SR,
are commercially available on request from Roche
NimbleGen.
DNA extraction
DNA for high-throughput sequencing was isolated from
spleen using a Qiagen DNeasy Blood and Tissue kit
(Qiagen, Santa Clarita, CA USA) or by phenol/chloro-
form extraction of nuclear pellets. Briefly, spleen sam-
ples were homogenized in ice-cold Tris lysis buffer (0.02
M Tris, pH 7.5, 0.01 M NaCl, 3 mM MgCl2). Homoge-
nates were then incubated in 1% sucrose, 1% NP40 to
release nuclei, which were subsequently pelleted by cen-
trifugation at 1,000 rpm, 4°C. Isolated nuclei were then
extracted by phenol chloroform in the presence of 1%
SDS. DNA for PCR was extracted from small (1 to 2
mm) tail biopsies by lysing in 200 ml of 50 mM NaOH
at 95°C for 10 minutes. Samples were neutralized by
adding 20 ml of 1 M Tris HCl, pH 8.0 and used directly
for PCR amplification.
Capture library preparation and hybridization amplification
Illumina PE libraries (Illumina, San Diego, CA, USA) were
constructed using Illumina’s Multiplexing Kit (part num-
ber PE-400-1001) with a few modifications. Size selection
w a sd o n eu s i n gt h eP i p p i nP r e pf r o mS a g eS c i e n c e ,I n c .
(Beverly, MA, USA). The target base pair selection size
was set at 430 bp. The entire 40 μl recovery product was
used as template in the pre-hybridization library amplifica-
tion (using ligation-mediated PCR (LMPCR)). Pre-hybridi-
zation LMPCR consisted of one reaction containing 50 μl
Phusion High Fidelity PCR Master Mix (New England
BioLabs, Ipswich, MA, USA; part number F-531L), 0.5 μM
of Illumina Multiplexing PCR Primer 1.0 (5’-AATGA-
TACGGCGACCACCGAGATCTACACTCTTTCCCTA-
CACGACGCTCTTCCGATCT-3’), 0.001 μM of Illumina
Multiplexing PCR Primer 2.0 (5’-GTGACTGGAGTTCA-
GACGTGTGCTCTTCCGATCT-3’), 0.5 μM of Illumina
PCR Primer, Index 1 (or other index at bases 25-31; 5’-
CAAGCAGAAGACGGCATACGAGAT(CGTGATG)
TGACTGGAGTTC-3’), 40 μl DNA, and water up to 100
μl. PCR cycling conditions were as follows: 98°C for 30 s,
followed by 8 cycles of 98°C for 10 s, 65°C for 30 s, and
72°C for 30 s. The last step was an extension at 72°C for 5
minutes. The reaction was then kept at 4°C until further
processing. The amplified material was cleaned with a
Qiagen Qiaquick PCR Purification Kit (part number
28104) according to the manufacturers instructions,
except the DNA were eluted in 50 μl of water. DNA was
quantified using the NanoDrop-1000 (Wilmington, DE,
USA) and the library was evaluated electrophoretically
with an Agilent Bioanalyzer 2100 (Santa Clara, CA, USA)
using a DNA1000 chip (part number 5067-1504). Sample
multiplexing was performed in some cases, after capture
and prior to sequencing.
Fairfield et al. Genome Biology 2011, 12:R86
http://genomebiology.com/2011/12/9/R86
Page 9 of 12Liquid phase sequence capture and processing
Prior to hybridization the following components were
added to a 1.5 ml tube: 1.0 μg of library material, 1 μlo f
1,000 μM oligo 5’- AATGATACGGCGACCACCGA-
GATCTACACTCTT TCCCTACACGACGCTCTT CCG
ATC*T-3’ (asterisk denotes phosphorothioate bond), 1 μl
of 100 μMo l i g o5 ’ CAAGCAGAAGACGGCATACGA-
GATCGTGATGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATC*T-3’ (bases 25 to 31 correspond to index
primer 1), and 5 μg of Mouse COT-1 DNA (part number
18440-016; Invitrogen, Inc., Carlsbad, CA, USA). Samples
were dried down by puncturing a hole in the 1.5-ml tube
cap with a 20 gauge needle and processing in an Eppen-
dorf Vacufuge (San Diego, CA, USA) set to 60°C for
20 minutes. To each sample 7.5 μl NimbleGen SC Hybri-
dization Buffer (part number 05340721001) and 3.0 μl
NimbleGen Hybridization component A (part number
05340721001) were added, sample was vortexed for 30 s,
centrifuged, and placed in a heating block at 95°C for
10 minutes. The samples were again mixed for 10 s, and
spun down. This mixture was then transferred to a
0.2-ml PCR tube containing 4.5 μl of Mouse Exome Solu-
tion Phase probes and mixed by pipetting up and down
ten times. The 0.2 ml PCR tubes were placed in a ther-
mocylcer with heated lid at 47°C for 64 to 72 hours.
Washing and recovery of captured DNA were performed
as described in chapter 6 of the NimbleGen SeqCap EZ
Exome SR Protocol version 2.2 (available from the Roche
NimbleGen website) [11]. Samples were then quality
checked using quantitative PCR as described in chapter
8 of the SR Protocol version 2.2 [10]. Sample enrichment
was calculated and used as a means of judging capture
success. Mean fold enrichment greater than 50 was con-
sidered successful and sequenced. NimbleGen Sequence
Capture Control (NSC) quantitative PCR assay NSC-
0272 was not used to evaluate captures in these
experiments.
Post-hybridization LMPCR
Post-hybridization amplification (for example, LMPCR
via Illumina adapters) consisted of two reactions for each
sample using the same enzyme concentration as the pre-
capture amplification, but a modified concentration,
2 uM, and different versions of the Illumina Multiplexing
1.0 and 2.0 primers were employed: forward primer 5’-
AATGATACGGCGACCACCGAGA and reverse primer
5’-CAAGCAGAAGACGGCATACGAG. Post-hybridiza-
tion amplification consisted of 16 cycles of PCR with
identical cycling conditions as used in the pre-hybridiza-
tion LMPCR (above), with the exception of the annealing
temperature, which was lowered to 60°C. After comple-
tion of the amplification reaction, the samples were puri-
fied using a Qiagen Qiaquick column following the
manufacturer’s recommended protocol. DNA was quan-
tified spectrophotometrically, and electrophoretically
evaluated with an Agilent Bioanalyzer 2100 using a
DNA1000 chip (Agilent). The resulting post-capture
enriched sequencing libraries were diluted to 10 nM and
used in cluster formation on an Illumina cBot and PE
sequencing was done using Illumina’sG e n o m eA n a l y z e r
IIx or Illumina HiSeq. Both cluster formation and PE
sequencing were performed using the Illumina-provided
protocols.
High-throughput sequencing data analysis
Mapping, SNP calling and annotation
The sequencing data were mapped using Maq, BWA (Bur-
rows-Wheeler alignment tool) and/or GASSST (global
alignment short sequence search tool) and SNP calling
was performed using SAMtools [25] and/or GenomeQuest
[26]. SNP annotation was performed using GenomeQuest,
custom scripts and Galaxy tools. Alignments were visua-
lized with the UCSC genome browser, Integrated Geno-
mics Viewer (Broad Institute) and/or SignalMap (Roche
NimbleGen).
Validation
Candidate mutations were validated by PCR amplifica-
tion and sequencing of affected and unaffected samples if
available from the mutant colony or from archived sam-
ples. Sequencing data were analyzed using Sequencher
4.9 (Gene Codes Corp., Ann Arbor, MI, USA). Primers
were designed using Primer3 software [27].
RT-PCR
Total RNA was isolated from heterozygous and homo-
zygous tail biopsies and/or embryos using the RNeasy
Mini Kit (Qiagen) according to the manufacturer’sp r o -
tocols. Total RNA (1 μg) was reverse transcribed into
cDNA using the SuperScript III First-Strand Synthesis
SuperMix for quantitative RT-PCR (Invitrogen) accord-
ing to the manufacturer’sp r o t o c o l s .c D N A( 3μl) was
used as template in a 30 μl PCR with the following
cycling conditions for all primers (0.4 μM final concen-
tration): 94°C (45 s), 56°C (45 s), 72°C (45 s) for 30
cycles. Primers used for Cleft were Cleft_11-14f (5’-
CTGGAAAACCTGGTGACGAC) and Cleft_11-14R (5’-
ACCAGCTTCCCCCTTAGC).
Additional material
Additional file 1: Summary statistics for the alpha and beta exome
probe pools.
Additional file 2: Comparison of 2 × 76-bp datasets from four
independent captures of female C56BL/6J DNA and one capture of
male C57BL/6J compared to alpha data from one capture of male
C57BL/6J.
Additional file 3: Additional data on mutant exomes sequenced in
this study. Genetic background, size of mapped intervals, genotype of
sequenced sample and percentage of SNVs identified are provided.
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Page 10 of 12Additional file 4: Data generated from exome sequencing of
mutant and control exomes (2 × 40 bp, 2 × 76 Illumina or 2 × 100
HiSeq).
Additional file 5: Seventeen variants passing filter in a C57BL/6J
exome. The genome coordinate and gene annotation for each variant
are provided. Comparison of these variants with the high-throughput
sequencing data for 17 inbred strains available from Sanger Mouse
Genomes Project revealed three exonic SNVs that are likely unique to the
C57BL/6J exome.
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